Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 1974972, 4 pages
http://dx.doi.org/10.1155/2016/1974972
Research Article

Different Vancomycin Immunoassays Contribute to the Variability in Vancomycin Trough Measurements in Neonates

1Institute of Pharmacology, Clinical Pharmacology and Toxicology, Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia
2Division of Pediatric Pharmacology and Pharmacometrics, University of Basel Children’s Hospital, 4056 Basel, Switzerland
3Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
4Neonatal Intensive Care Unit, University Hospitals Leuven, 3000 Leuven, Belgium
5Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven and Pharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium
6Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia
7Clinical Pharmacology Unit, University Children’s Hospital, 11000 Belgrade, Serbia
8Division of Pediatric Clinical Pharmacology, Children’s National Medical Center, Washington, DC 20010, USA
9Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children’s Hospital, 3000 CB Rotterdam, Netherlands

Received 18 February 2016; Accepted 31 July 2016

Academic Editor: Giulio Mengozzi

Copyright © 2016 Janko Samardzic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. de Hoog, J. W. Mouton, and J. N. van den Anker, “Vancomycin: pharmacokinetics and administration regimens in neonates,” Clinical Pharmacokinetics, vol. 43, no. 7, pp. 417–440, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. J. N. van den Anker, “Getting the dose of vancomycin right in the neonate,” International Journal of Clinical Pharmacology and Therapeutics, vol. 49, no. 4, pp. 247–249, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. G. M. Pacifici and K. Allegaert, “Clinical pharmacokinetics of vancomycin in the neonate: a review,” Clinics, vol. 67, no. 7, pp. 831–837, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. B. J. Anderson, K. Allegaert, J. N. van den Anker, V. Cossey, and N. H. G. Holford, “Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance,” British Journal of Clinical Pharmacology, vol. 63, no. 1, pp. 75–84, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. E. J. Begg, M. L. Barclay, and C. J. M. Kirkpatrick, “The therapeutic monitoring of antimicrobial agents,” British Journal of Clinical Pharmacology, vol. 47, no. 1, pp. 23–30, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. W. Zhao, F. Kaguelidou, V. Biran et al., “External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings,” British Journal of Clinical Pharmacology, vol. 75, no. 4, pp. 1068–1080, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. K. König, U. Kobold, G. Fink et al., “Quantification of vancomycin in human serum by LC-MS/MS,” Clinical Chemistry and Laboratory Medicine, vol. 51, no. 9, pp. 1761–1769, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Shipkova, D. T. Petrova, A. E. Rosler et al., “Comparability and imprecision of 8 frequently used commercially available immunoassays for therapeutic drug monitoring,” Therapeutic Drug Monitoring, vol. 36, no. 4, pp. 433–441, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Oyaert, N. Peersman, D. Kieffer et al., “Novel LC-MS/MS method for plasma vancomycin: comparison with immunoassays and clinical impact,” Clinica Chimica Acta, vol. 441, pp. 63–70, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. D. F. Legatt, G. B. Blakney, T. N. Higgins et al., “The effect of paraproteins and rheumatoid factor on four commercial immunoassays for vancomycin: implications for laboratorians and other health care professionals,” Therapeutic Drug Monitoring, vol. 34, no. 3, pp. 306–311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Vandendriessche, K. Allegaert, V. Cossey, G. Naulaers, V. Saegeman, and A. Smits, “Prospective validation of neonatal vancomycin dosing regimens is urgently needed,” Current Therapeutic Research—Clinical and Experimental, vol. 76, pp. 51–57, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Allegaert and J. N. van den Anker, “Creatinine-based vancomycin dosing regimens in neonates: there is more to consider than the variation in drug assay,” Pharmacotherapy, vol. 32, no. 9, pp. e174–e175, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Tudela, G. Muñoz, and J. A. Muñoz-Guerra, “Matrix effect marker for multianalyte analysis by LC-MS/MS in biological samples,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 901, pp. 98–106, 2012. View at Publisher · View at Google Scholar · View at Scopus